Jim Cramer on Merck & Co., Inc. (MRK): ‘Right Now, The Stock’s Well-ensconced A Few Points Around 52-week Low’
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors
Merck & Co. Inc. closed $34.98 below its 52-week high ($134.63), which the company achieved on June 25th.
Exclusive: Kennedy played key role in Gardasil vaccine case against Merck
Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...
Merck sees 2025 launch for simpler version of cancer drug Keytruda
Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...
What’s In Store For Merck Stock In 2025?
Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.
Merck Gets China Nod on HPV Shot for Men Amid Sales Slump
China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...
Merck & Co.’s Accelerated Keytruda Launch and Strategic Updates Bolster Long-term Growth Prospects
Analyst Akash Tewari of Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), retaining the price target of ...
Despite Setbacks, Moderna Sees Opportunity In Avian Flu, Merck Partnership
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
Merck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda Challenges
Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...
Hosted on MSN5d
Merck Speeds Up Launch of New Keytruda Version as Patent Expiration Nears
Keytruda sales account for roughly 40% of Merck’s revenue, and the company has been focused on the 2028 patent expiration for ...
Merck & Co. Inc. stock underperforms Friday when compared to competitors
Shares of Merck & Co. Inc. MRK shed 2.76% to $97.92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.00% to 5,996.66 and ...